02 August 2023
02 August 2023
Nick Hartshorne-Evans, CEO and founder of Pumping Marvellous Foundation, discusses the importance of patient groups in the R&D process.
The grant will support the early development of Amygdala’s ALDH2 Inhibitor currently in pre-clinical development.
Reece has reported that R327 was safe and well tolerated in the first cohort of patients in the Phase I/II UTI trial.
PureTech Health is developing an orally administered prodrug of neurosteroid allopregnanolone.
The company received the FDA’s orphan drug designation for QN-302 in January for treating pancreatic cancer.
As government funding for Covid-19 medicine tapers off, companies are returning to normal profits.
Participants in stage one will receive either ascending doses of the drug or placebo in addition to hypothermia for 72 hours.
The subject will be injected with DR10624 subcutaneously or will receive a placebo for 12 weeks.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
